ALTER-GREF: Randomized prospective phase II clinical trial using post-transplantation cyclophosphamide for prevention of GVHD in haploidentical and HLA 9/10 mismatched unrelated donors hematopoietic stem cell transplant

assignment_turned_inproject

Funder: Institut National du CancerProject code: INCa-DGOS-11089 Call for proposal: PHRC16

Funded under: PHRC

ALTER-GREF: Randomized prospective phase II clinical trial using post-transplantation cyclophosphamide for prevention of GVHD in haploidentical and HLA 9/10 mismatched unrelated donors hematopoietic stem cell transplant

- Summary
- DMPs

Partners

HUS , Groupe Hospitalier Pitié Salpétrière , HUG , Hôpital Claude Huriez , Centre Hospitalier Universitaire de Poitiers , Centre Hospitalier Universitaire de Toulouse , Centre Hospitalier Universitaire de Limoges , Institut Paoli-Calmettes- (IPC) , CHRU MTP , Hôpital Necker- Enfants malades , HCL , Institut de cancérologie Lucien Neuwirth , CHU Nantes - Hôtel Dieu , CHU , Groupe Hospitalier Henri Mondor - Albert Chenevier

Data Management Plans

Start a new DMP in Argos

Found an issue? Give us feedback

Select content type to embed

All Research products

arrow_drop_down

<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=inca________::b21f6523bc51502d24ff3e6940f669d8&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

ALTER-GREF: Randomized prospective phase II clinical trial using post-transplantation cyclophosphamide for prevention of GVHD in haploidentical and HLA 9/10 mismatched unrelated donors hematopoietic stem cell transplant

ALTER-GREF: Randomized prospective phase II clinical trial using post-transplantation cyclophosphamide for prevention of GVHD in haploidentical and HLA 9/10 mismatched unrelated donors hematopoietic stem cell transplant

Loading